Current guidelines for management of advanced breast cancer recommend hormone-directed treatments as first-line therapy for estrogen- and HER2-receptor positive disease, whereas chemotherapy is recommended for receptor-negative disease. Here, ERBB2 is linked to breast carcinoma.